Entries |
Document | Title | Date |
20080207875 | Preventive and Therapeutic Use of polypeptides from African Swine Virus as Vaccines - The present invention relates to the use of selected polypeptides from African Swine virus for the prevention and therapy of African Swine infections as well as other infections, including immune deficiencies in mammals and humans. | 08-28-2008 |
20080227953 | c-Mpl LIGAND POLYPEPTIDE - A meg-CSF/thrombopoietin-like protein that is present in plasma of irradiated pigs has been purified. This protein, the porcine Mpl ligand polypeptide (ML), binds to and activates the c-Mpl receptor protein, a member of the cytokine receptor superfamily. The isolated Mpl ligand stimulates both megakaryocytopoiesis and thrombopoiesis. | 09-18-2008 |
20080227955 | Nematode PAN and ZP Receptor-Like Sequences - Nucleic acid molecules from nematodes encoding PAN and ZP domain containing receptor polypeptides are described. PANZP polypeptide sequences are also provided, as are vectors, host cells, and recombinant methods for production of PANZP nucleotides and polypeptides. Also described are screening methods for identifying inhibitors and/or activators, as well as methods for antibody production. | 09-18-2008 |
20080234465 | EXPRESSION IN FILAMENTOUS FUNGI OF PROTEASE INHIBITORS AND VARIANTS THEREOF - Described herein are protease inhibitors, variants thereof and methods for their production. | 09-25-2008 |
20080234466 | Delivery method for the tumor-specific apoptosis-inducing activity of apoptin - The invention relates to the field of apoptosis. The invention provides novel therapeutic substances, for example, novel therapeutic proteinaceous compounds that can contain apoptin alone or jointly with other proteinaceous protein or protein fragments, especially in those cases when cells are derailed such as cancer-, autoimmune-derived cells. | 09-25-2008 |
20080262198 | Cross-Linkable Glycoproteins and Methods of Making the Same - Non-naturally occurring peptides/polypeptides/proteins comprising the crosslinking motif, Tyr-X-Tyr, wherein X is any amino acid, and methods of preparing the same. | 10-23-2008 |
20080269462 | Peptide inhibitors of HIV entry - Described herein are chimeric peptides comprising a soluble trimeric coiled-coil and all or a portion of the N-peptide region of HIV gp41. These molecules are stable, trimeric coiled-coils that inhibit HIV entry into cells, such as human cells. Such peptides can be further assessed to demonstrate their ability to serve as potent anti-HIV therapeutic molecules and thus, as therapeutic molecules or drugs. | 10-30-2008 |
20080275214 | REPLIKINS AND MENTODS OF IDENTIFYING REPLIKIN-CONTAINING SEQUENCES - The present invention provides methods for identifying a class of peptides referred to as replikins and methods of using replikins to stimulate the immune system of a subject. The method of identifying replikin peptides is based on identifying amino acid sequences comprising 7 to about 50 amino acids that contain (1) at least one lysine residue located six to ten residues from a second lysine residue; (2) at least one histidine residue; and (3) at least 6% lysine residues. | 11-06-2008 |
20080281076 | IL-6 binding proteins - Polypeptides comprising monomer domains that bind to IL-6, or portions thereof, are provided. | 11-13-2008 |
20080281077 | Protein Sweetener - Disclosed herein are sweet proteins that are variants of Brazzein, and nucleotide sequences capable of expressing them. Through a replacement of a tyrosine residue at the C terminus in the naturally occurring Brazzein sequence, or the insertion of two residues (at least one being isoleucine, glycine or proline) before the N terminus of wild type Brazzein, sweetness potency, the taste profile and sweetness strength are improved. | 11-13-2008 |
20080287651 | Silk Thread Containing Spider Thread Protein and Silk Worm Producing the Silk Thread - A transgenic silkworm having transferred therein a gene which encodes spider thread protein having desired properties of high strength and high elasticity while leaving the silkworm fibroin H chain gene intact, by means of utilizing a transposon function, is used to produce in the transgenic silkworm a spider thread protein having the desired properties without lowering the strength or elasticity of silk thread produced by the transgenic silkworm, thereby providing hybrid silk of spider and silk threads having the desired properties. | 11-20-2008 |
20090018310 | PEPTIDES AND PEPTIDE DERIVATIVES, THE PRODUCTION THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION - The invention relates to peptides and peptide derivatives of the following general Formulas (Ia) and (Ib) as well as in particular anti-inflammatory drugs containing these peptides. | 01-15-2009 |
20090023893 | USE OF ANTIMICROBIAL PROTEINS AND PEPTIDES FOR THE TREATMENT OF OTITIS MEDIA AND PARANASAL SINUSITIS - The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof. | 01-22-2009 |
20090030178 | Cell permeable bioactive peptide conjugates - Cell permeable bioactive peptide conjugates having a first bioactive peptide region coupled to a second transport peptide region allowing transfer of the first bioactive peptide region and the second transport peptide region across biological membranes to enter intact living cells for regulation of biological responses. | 01-29-2009 |
20090036648 | EGVI Endoglucanase and Nucleic Acids Encoding the Same - The present invention provides a novel endoglucanase nucleic acid sequence, designated egl6, and the corresponding EGVI amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding EGVI, recombinant EGVI proteins and methods for producing the same. | 02-05-2009 |
20090043073 | Alpha-fetoprotein peptides and uses for imaging - The invention provides diagnostic procedures wherein the presence or absence of a cell-proliferating disorder, e.g., a breast cancer, may be determined. The imaging agents of the invention include alpha-fetoprotein hydrophilic analogs which have been determined to target cancers, e.g., breast cancer, and are also anti-cell proliferating in nature. These modulators contain amino acid structures which are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures. The imaging agents of the invention further comprise an imaging moiety that allows for the imaging of the area targeted by the imaging agent. | 02-12-2009 |
20090043074 | Use of Ghrelin Splice Variant for Treating Cachexia and/or Anorexia and/or Anorexia-Cachexia and/or Malnutrition and/or Lipodystrophy and/or Muscle Wasting and/or Appetite-Stimulation - The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of loss of body weight and body fat, prophylaxis or treatment of cachexia, stimulation of appetite, stimulation of food intake, stimulation of weight gain, or increasing body fat mass, or increasing body lean mass. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to the use of a ghrelin splice variant-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to a number of new ghrelin splice variant-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin splice variant-like compounds. | 02-12-2009 |
20090048428 | PEPTIDE TAGS FOR THE EXPRESSION AND PURIFICATION OF BIOACTIVE PEPTIDES - Peptide tags, referred to here as inclusion body tags, are disclosed and are useful for the generation of insoluble fusion peptides. The fusion peptides comprise at least one inclusion body tag operably linked to a peptide of interest. Expression of the fusion peptide in a host cell results in a product that is insoluble and contained within inclusion bodies in the cell and/or cell lysate. The inclusion bodies may then be purified and the protein of interest may be isolated after cleavage from the inclusion body tag. | 02-19-2009 |
20090062510 | Human Chemotactic Cytokine I Polypeptides - Human chemotactic cytokine I polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host. | 03-05-2009 |
20090069535 | Ligand (ACT-4-L) to a Receptor on the Surface of Activated CD4+ T-Cells - The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4 | 03-12-2009 |
20090088554 | HDM2-INHIBITOR COMPLEXES AND USES THEREOF - The present invention includes crystallized HDM2 peptides as well as descriptions of the X-ray diffraction patterns of the crystals. The diffraction patterns allow the three dimensional structure of HDM2 to be determined at atomic resolution so that ligand binding sites on HDM2 can be identified and the interactions of ligands with HDM2 amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MDM2 and HDM2 oncoproteins. | 04-02-2009 |
20090088555 | 44 Human Secreted Proteins - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. | 04-02-2009 |
20090093614 | SELF-ASSEMBLED PROTEINS AND RELATED METHODS - The present invention provides user-directed construction of novel specific homo- and hetero-dimeric, and multimeric assemblages of proteins. The present invention is comprised of a family of peptide sequences that forms links between proteins, where the peptide sequences produce a hook or loop which supports specific self-assembly of dimers of the proteins to which they are attached. The hook or loop may have a short aliphatic repeat and a metal binding loop. Also provided is a method of constructing a hook motif of metal binding loop sequences attached to at least one aliphatic carbon sequence to produce homo-dimeric, hetero-dimeric and multimeric assemblages of proteins. | 04-09-2009 |
20090111970 | CANINE AND FELINE IMMUNOREGULATORY PROTEINS, NUCLEIC ACID MOLECULES, AND USES THEREOF - The present invention relates to canine interleukin-5 proteins; canine interleukin-5 nucleic acid molecules, including those that encode canine interleukin-5 proteins; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal. | 04-30-2009 |
20090118468 | Cynomolgus Prostate Specific Antigen - Isolated polynucleotides encoding Cynomolgus monkey prostate specific antigen and polypeptides obtainable from the polynucleotides and uses are disclosed. | 05-07-2009 |
20090118469 | High-Affinity Antagonists of ELR-CXC Chemokines - The present invention provides novel polypeptide sequences, methods for production thereof and uses thereof for novel ELR-CXC chemokine receptor agonists and antagonists. | 05-07-2009 |
20090131634 | Method for Preparing Cell Fraction Containing Hemangioblasts - Mouse PCLP1 was identified by expression cloning with the use of a monoclonal antibody against a surface antigen of a cell line derived from mouse AGM. By fractionating PCLP1-positive/CD45-negative cells and culturing them in vitro, it was clarified that these cells differentiate into endothelial-like cells, angioblast-like cells, and hematopoietic cells. By transferring the PCLP1-positive/CD45-negative cells into a mouse defective in the hematopoietic function, the hematopoietic system was reconstructed over a long period of time. These facts indicate that the PCLP1-positive/CD45-negative cells contain mammalian hemangioblasts capable of expressing the activity as long-term repopulating hematopoietic stem cells (LTR-HSC). The present invention provides a method for preparing a cell fraction containing hemangioblasts, the cell fraction prepared by the method, and use of this cell fraction. | 05-21-2009 |
20090137778 | REPLIKIN PEPTIDES AND ANTIBODIES THEREFORE - The present invention provides a new class of peptides related to rapid replication and their use in diagnosing, preventing and treating disease. | 05-28-2009 |
20090143566 | Growth Factor Analogs - The invention provides synthetic heparin-binding growth factor analogs of formulas I or II as given in the specification, having two peptide chains branched from a dipeptide branch moiety composed of at least one and preferably two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices. | 06-04-2009 |
20090149630 | Stabilized Alpha Helical Peptides and Uses Thereof - Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death. | 06-11-2009 |
20090171068 | Method of peptide synthesis - A method for solid phase synthesis of Thymosin α | 07-02-2009 |
20090171069 | Peptides And Apl-Type Derivatives Of Hsp60 And Pharmaceutical Compositions - Peptides of human heat shock protein of 60 kDa, that constitute epitopes for T cells, as well as their derived peptides, which are modified at the contact sites with the MHC molecule, are useful to induce mechanisms of peripheral tolerance, in particular mechanisms of anergy or mediated by clones of regulatory T cells in patients with Rheumatoid Arthritis. The invention also refers pharmaceutical compositions comprising such peptides for the treatment of Rheumatoid Arthritis. | 07-02-2009 |
20090182119 | CATALYTICALLY ACTIVE PEPTIDES - A catalytically active peptide comprising an imidazole function in position i flanked by at least one functional group to be amidated in position i+3+4k, where k is an integer equal to or higher than −1 or in position i−4−4n, wherein n is an integer equal to or higher than 0, characterized in that it also comprises at least one activating group in position i+4+4n or i−3−4n, respectively, wherein n is as above. | 07-16-2009 |
20090187004 | EXPRESSION SYSTEM FOR ENHANCING SOLUBILITY AND IMMUNOGENEICITY OF RECOMBINANT PROTEINS - Expression system for enhancing solubility and immunogenicity of recombinant proteins. The expression system includes a protein expression vector that contains a chimeric gene encoding a chimeric protein comprising: (a) a first polypeptidyl fragment at the N-terminal end of the chimeric protein, containing a protein transduction domain (PTD), or a fragment thereof, having HIV Tat PTD activity; (b) a second polypeptidyl fragment at the C-terminal end of the first polypeptidyl fragment, containing a J-domain, or a fragment thereof, having heat shock protein 70 (Hsp70)-interacting activity; and (c) a third polypeptidyl fragment at the C-terminal end of the second polypeptidyl fragment, containing a target protein or polypeptide. | 07-23-2009 |
20090203878 | TRYPTOPHAN AS A FUNCTIONAL REPLACEMENT FOR ADP-RIBOSE-ARGININE IN RECOMBINANT PROTEINS - A method is disclosed for producing a polypeptide with a modified activity or stability, by replacing an arginine residue capable of being ADP-ribosylated with a tryptophan or a phenylalanine. In one embodiment, compositions are provided that include polypeptides, such as alpha defensin, with arginine-to-tryptophan or arginine-to-phenylalanine substitutions, where the arginine residue is capable of being ADP-ribosylated. In another embodiment, methods are disclosed for modifying an immune response in a subject. | 08-13-2009 |
20090215983 | Compounds and methods for inhibiting hepatitis C virus replication - The inventors have discovered that an ATPase-deficient dominant-negative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal structure of a multi-enzyme NS3 complex on a DNA substrate is also provided. The inventors have tested a peptide matching the sequence of a portion of NS3 that interacts with another NS3 molecule for inhibiting HCV replication. The peptide inhibits HCV replication. Accordingly, the invention provides a method of inhibiting HCV replication in cells infected with HCV involving transforming the cells with a vector expressing a dominant-negative mutant NS3 gene. The invention also provides a method of inhibiting HCV replication in cells infected with HCV involving administering to the cells a dominant-negative mutant NS3 protein. The invention also provides peptides and agents that inhibit HCV replication and methods of identifying agents that inhibit HCV replication. | 08-27-2009 |
20090215984 | CONVERSION OF APOPTOTIC PROTEINS - Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-X | 08-27-2009 |
20090221789 | Crystalline Polypeptides - Crystalline formulations of therapeutic peptides, along with methods for making and using the same, are provided. | 09-03-2009 |
20090240028 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides - The invention provides synthesis and application of new structural well defined branched polymers as protraction agents for peptide and protein. | 09-24-2009 |
20090259019 | MASP-2, A COMPLEMENT FIXING ENZYME, AND USES FOR IT - The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway. | 10-15-2009 |
20090264618 | Compounds With a Branched Linker - Disclosed herein are branched linkers of the formula: | 10-22-2009 |
20090281277 | PEPTIDES CAPABLE OF BINDING TO SERUM PROTEINS AND COMPOUNDS, CONSTRUCTS AND POLYPEPTIDES COMPRISING THE SAME - The present invention relates to amino acid sequences that are capable of binding to serum proteins; to compounds, proteins, polypeptides, fusion proteins or constructs comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; and to uses of such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs. | 11-12-2009 |
20090286954 | Human cDNA Clones Comprising Polynucleotides Encoding Polypeptides and Methods of Their Use - The invention provides novel human full-length cDNA clones, novel polynucleotides, related polypeptides, related nucleic acid and polypeptide compositions, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and use these cDNA clones, polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic, prophylactic and therapeutic applications. The compositions and methods of the invention are useful in treating proliferative disorders, e.g., cancers, and inflammatory, immune, bacterial, and viral disorders. | 11-19-2009 |
20090292107 | COMPOSITION AND METHOD TO ALTER LEAN BODY MASS AND BONE PROPERTIES IN A SUBJECT - The present invention pertains to a method for decreasing the body fat proportion, increasing lean body mass (“LBM”), increasing bone density, or improving the rate of bone healing, or all, of a subject. Overall, the embodiments of the invention can be accomplished by delivering a heterologous nucleic acid sequence encoding GHRH or functional biological equivalent thereof into the cells of the subject and allowing expression of the encoded gene to occur while the modified cells are within the subject. For instance, when such a nucleic acid sequence is delivered into the specific cells of the subject tissue specific constitutive expression is achieved. Furthermore, external regulation of the GHRH or functional biological equivalent thereof gene can be accomplished by utilizing inducible promoters that are regulated by molecular switch molecules, which are given to the subject. The preferred method to deliver the constitutive or inducible nucleic acid encoding sequences of GHRH or the functional biological equivalents thereof is directly into the cells of the subject by the process of in vivo electroporation. A decrease the body fat proportion and an increase in lean body mass (“LBM”), or both of a subject is achieved by the delivery of GHRH or functional biological equivalent thereof as described herein by into the subject as recombinant proteins. In addition, an increase in bone density and improvement in the rate of bone healing is also achieved. | 11-26-2009 |
20090299034 | Collagen-related peptides - The present invention relates to a collagen-related polypeptide (CRP) having hydrophobic amino acid groups at the N- and C-termini capable of non-covalent self-assembly into collagen mimetic triple helices and fibrils thereof and the synthesis, methods of use and compositions thereof. | 12-03-2009 |
20090299035 | PROTEIN APPROPRIATE FOR ORIENTATION-CONTROLLED IMMOBILIZATION AND IMMOBILIZATION CARRIER ON WHICH THE PROTEINS ARE IMMOBILIZED - An object of the present invention is to provide a novel protein having the following amino acid sequence altered for specifically and efficiently binding a protein to an immobilization carrier via the carboxy terminus. The protein is used for immobilizing a portion represented by R1-R2 on an immobilization carrier, comprising the amino acid sequence represented by the general formula R1-R2-R3-R4-R5 [wherein:
| 12-03-2009 |
20090318666 | Synthetic Dog/Human Chimeric C-C Chemokine Receptor 2B - Disclosed herein are polynucleotides encoding a chimeric C—C chemokine receptor 2B, the encoded polypeptides thereof and methods of making and using said polynucleotides and polypeptides. | 12-24-2009 |
20090326196 | Proteins Containing a Fluorinated Amino Acid, and Methods of Using Same - One aspect of the invention relates to a polypeptide comprising at least one fluorinated amino acid. Another aspect of the invention relates to a method for modifying a first polypeptide, comprising replacing at least one amino acid in said first polypeptide with a fluorinated amino acid, thereby producing a second polypeptide with increased stability relative to said first polypeptide. | 12-31-2009 |
20100016547 | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient - The present invention related to providing a novel medicine for treating diabetes. It is possible to provide a GLP-1 derivative which is resistant to enzyme degradation by glycosylation of the peptide side chain. | 01-21-2010 |
20100041868 | Conserved neisserial antigens - To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of | 02-18-2010 |
20100048862 | Ferroportin1 nucleic acids, proteins, antibodies and methods - Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation, and functions as an iron exporter when expressed in | 02-25-2010 |
20100048863 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK - A method of diagnosing a disease or syndrome associated with disregulation of Neuregulin-4 (NRG-4), Aa novel ErbB-4 ligand, referred to herein as Neuregulin-4 (NRG-4)in a subject is disclosed. The method comprising: (a) obtaining a sample from a subject; (b) incubating the sample with at least one oligonucleotide or oligonucleotide analog of at least bases, said oligonucleotide or oligonucleotide analog capable of hybridizing to a portion of a polynucleotide strand encoding NRG-4 to thereby diagnosing the disease, condition or syndrome associated with disregulation of NRG-4. | 02-25-2010 |
20100063250 | TRUNCATED TAU PROTEINS - Described are novel N- and C-terminally double truncated tau molecules, (“type IA, IB, IIA and IIB tau molecules”) as well as methods for providing these molecules, both from recombinant and biological sources. Moreover, screening methods using these molecules in connection with Alzheimer's diagnosis and therapy are provided. | 03-11-2010 |
20100069608 | BIOMATERIAL WITH FUNCTIONALISED SURFACES - There is provided a biomaterial having a functionalised surface which comprises bi-functional semi-dendrimers. The biomaterial may be ceramic, metallic and/or polymeric. It will usually be in the form of a solid, but could be a semi-solid or hydrogel. There is also provided a method of making a biomaterial having a functionalised surface which comprises bi-functional semi-dendrimers, said method comprising adsorbing, grafting or synthesising in situ bi-functional semi-dendrimers onto the surface of a biomaterial. There is further provided a biomedical device which is coated with or formed from a biomaterial having a functionalised surface which comprises bi-functional semi-dendrimers. The biomedical device may be a medical implant, for example, such as a stent, artificial hip joint or replacement heart valve. FIG. | 03-18-2010 |
20100076173 | SYSTEMS AND METHODS FOR GENERATING PEPTIDES - Antimicrobial peptides are small proteins used by the innate immune system to combat bacterial infection in multicellular eukaryotes. There is mounting evidence that these peptides are less susceptible to bacterial resistance than traditional antibiotics and that they may form the basis for a novel class of therapeutics. Systems and methods may treat the amino acid sequences of these peptides as a formal language and build a set of right-linear grammars that describe this language. These grammars may allow for rationally designed novel antimicrobial peptides in silico. These peptides conform to the syntax of natural antimicrobial peptides lack significant homology to any natural sequences, thus populating a previously unexplored region of protein sequence space. Synthesis of these peptides, leads to de novo AmPs. | 03-25-2010 |
20100076174 | ErbB Interface Peptidomimetics And Methods Of Use Thereof - Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 03-25-2010 |
20100099844 | Hydrophobin Solution Containing Antifoam - Aqueous solution containing at least 300 mg/l of hydrophobin and at least 0.3 mg/l of antifoam, wherein the antifoam/hydrophobin weight ratio is below 0.2, preferably below 0.15, more preferably below 0.1. | 04-22-2010 |
20100105863 | Method For Producing Acylated Peptides - The present invention provides a method for acylating one or more amino groups of a peptide where the acylation reaction is to be performed in an aqueous mixture containing less than 10% w/w aprotic polar solvent. | 04-29-2010 |
20100113740 | PEPTIDES AND PEPTIDE DERIVATIVES, THE PRODUCTION THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION - The invention relates to peptides and peptide derivatives of the following general Formulas Ia and Ib | 05-06-2010 |
20100125127 | B7-related nucleic acids and polypeptides useful for immunomodulation - The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject. | 05-20-2010 |
20100130720 | ARTIFICIAL BINDING PROTEINS BASED ON A MODIFIED ALPHA HELICAL REGION OF UBIQUITIN - The present invention is directed to a method for the generation of binding proteins derived from the protein super-family of ubiquitin like proteins with modifications in their alpha helical region as well as to a protein obtainable by said method. Furthermore, the invention provides the use of a protein for the specific recognition, binding and neutralization of a predescribed target molecule, for the detection, quantitative determination, separation and/or for the isolation of a corresponding binding partner and the use of a protein of the invention, for diagnosis, prophylaxis and treatment of diseases in which the corresponding binding partner is directly or indirectly involved. | 05-27-2010 |
20100130721 | IMMOBILIZED PROTEIN THAT IS IMMOBILIZED ONLY AT ITS AMINO TERMINUS IN ORIENTATION-CONTROLLED MANNER - This invention provides an immobilized protein bound to an immobilization carrier at a protein amino terminus via the sole α-amino group of the protein comprising an amino acid sequence containing neither lysine residues nor cysteine residues represented by the general formula S1-R1-R2, wherein: the sequences are oriented from the amino terminal side to the carboxy terminal side; the sequence of the S1 portion may be absent, but when the sequence of the S1 portion is present, the sequence of the S1 portion is a spacer sequence composed of amino acid residues other than lysine and cysteine residues; the sequence of the R1 portion is the sequence of a subject protein to be immobilized and contains neither lysine residues nor cysteine residues; and the sequence of the R2 portion may be absent, but when the sequence of the R2 portion is present, the sequence of the R2 portion is a spacer sequence composed of amino acid residues other than lysine and cysteine residues. | 05-27-2010 |
20100137560 | Oligopeptides and their use in cosmetics - The present invention relates to the cosmetic use of oligopeptides, cosmetic preparations which comprise such oligopeptides as well as certain oligopeptide derivatives themselves. | 06-03-2010 |
20100137561 | PROCESS FOR PREPARING THERAPEUTIC PEPTIDE - This application discloses processes for synthesizing human relaxin Chain B for treatment of diseases mediated by relaxin. This application in particular discloses processes of synthesizing the Chain B of human relaxin using a solid and solution phase (“hybrid”) approach. Generally, the approach includes synthesizing three different peptide intermediate fragments using solid phase chemistry. Solution phase chemistry is then used to couple the fragments. | 06-03-2010 |
20100145007 | CHIMERIC PEPTIDE ANTAGONIST FOR GPCR135 OR GPCR142 - The chimeric polypeptide R3(BΔ23-27)R/I5 is described, which is a high-affinity antagonist for GPCR1 35 and GPCR1 42 over LGR7. | 06-10-2010 |
20100145008 | OB-FOLD USED AS SCAFFOLD FOR ENGINEERING NEW SPECIFIC BINDERS - The present invention pertains to the field of protein engineering, and provides means for obtaining stable molecules that specifically bind to a target selected amongst a large variety of ligands families. In particular, the present invention provides methods for obtaining a molecule specifically binding to a target of interest, through a combinatorial mutation/selection approach with an OB-fold protein as a starting molecule. In particular, the target of interest can be of a different chemical nature form that of the native target of the OB-fold protein used as the starting molecule. | 06-10-2010 |
20100145009 | ANTIBODIES WHICH ARE DIRECTED AGAINST THE MARBURG I POLYMORPHISM OF FACTOR VII-ACTIVATING PROTEASE (FSAP), AND THEIR PREPARATION AND USE - The invention relates to antibodies which are directed against the FSAP Marburg I variant and to their preparation and use, in particular in therapy and diagnosis. The antibodies are characterized by the fact that they bind specifically to the FSAP MR I variant but not to the FSAP wild-type protein or other mutant variants which are characterized by amino acid substitutions at other positions in the FSAP protein. | 06-10-2010 |
20100145010 | Functional enhancement of antimicrobials - The present invention provides methods for adding functional hydrophobic, charge, polar, and other structural groups on antimicrobial compounds for enhancing the physicochemical properties of the antimicrobial compounds, thereby creating novel antimicrobial analogs with enhanced functions. | 06-10-2010 |
20100145011 | ALPHA-CONOTOXIN PEPTIDES - The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. | 06-10-2010 |
20100168382 | NEUROPLASTIN DERIVED PEPTIDES - The present invention relates to peptides derived from neuroplastin which are capable of inducing neurite outgrowth by modulating intracellular calcium concentration and activity of intracellular signalling molecules such as Akt, Erk1/2 and CREB through binding and/or modulation of receptor tyrosine kinases including but not limited to Fibroblast Growth Factor receptors (FGFRs). The peptides are derived from neuroplastin or fragments thereof. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein neuroplastin and/or receptor tyrosine kinases, including but not limited to FGFRs, play a prominent role. | 07-01-2010 |
20100184949 | Method for the mass expression of an antimicrobial peptide by using a translational coupling system - The present invention relates to a gene construct which is capable of achieving efficient production of an antimicrobial peptide in a microorganism, and a method for efficient mass production and separation of an antimicrobial peptide using the same. The gene construct of the present invention has a translationally coupled configuration of two independent and separate cistrons which encode an acidic peptide and a basic antimicrobial peptide, each having an opposite charge, under the control of a single promoter. The translationally coupled acidic peptide and basic antimicrobial peptide undergo charge-charge interaction simultaneously with expression thereof to neutralize the potential cytotoxicity of the antimicrobial peptide, resulting in prevention of antimicrobial peptide-mediated killing of host microorganisms. In addition, a conjugate of the acidic peptide and the antimicrobial peptide can be separated without chemical or enzymatic treatment. Therefore, it is possible to achieve easy mass production of antimicrobial peptides from recombinant microorganisms. | 07-22-2010 |
20100184950 | PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE - The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair. | 07-22-2010 |
20100184951 | Truncated BAFF Receptors - The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders. | 07-22-2010 |
20100190960 | Methods and Compositions for Detection of Ehrlichia chaffeensis (p120) - The invention provides methods and compositions for the detection of | 07-29-2010 |
20100197889 | POLYPEPTIDE AS STANDARD FOR PROTEOME ANALYSIS - The present invention provides a polypeptide as standard for peptide analysis by mass spectrometry comprising at least 16 peptides selected from the group consisting of the peptides of SEQ ID NO: 1 to SEQ ID NO: 22 or variants thereof, together with an artificial protein comprising the polypeptide, a vector comprising a nucleic acid encoding the polypeptide, a kit for proteome analysis, a selection of peptides for calibration an devaluation of mass spectrometers and chromatographs for proteome analyses and uses thereof. | 08-05-2010 |
20100197890 | Anti-cancer protein-platinum conjugates - The invention provides polypeptide-platinum conjugates comprising an anti-cancer platinum complex conjugated to polypeptides that bind relatively specifically to cancer cells, so as to direct the conjugates to cancer cells resulting in increased anti-cancer efficacy and decreased side-effects as compared to cisplatin and other conventional anti-cancer platinum complexes. | 08-05-2010 |
20100204445 | DOCKERIN POLYPEPTIDE AND METHOD OF PURIFYING RECOMBINANT FUSED PROTEIN USING THE SAME - The purpose of the invention is to provide a novel purification system allowing the efficient and economical production and purification of a recombinant fused protein, whereby the elution time at a low temperature can be reduced, since it has been a problem to be solved in the existing purification method using dockerin and cohesin. In this purification system, a dockerin polypeptide characterized in that the 14th amino acid in the subdomain 2 of dockerin originating from | 08-12-2010 |
20100204446 | USE OF NATRIURETIC PEPTIDES FOR TREATING ANGIOEDEMA SYNDROMES - The present invention relates to the use of a natriuretic peptide, urodilatin, for treating patients suffering from acute drug induced angioedema, such as ACE inhibitor related adverse events. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously for 18 hours to 72 hours. | 08-12-2010 |
20100204447 | USE OF ANITMICROBIAL PROTEINS AND PEPTIDES FOR THE TREATMENT OF OTITIS MEDIA AND PARANASAL SINUSITIS - The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof. | 08-12-2010 |
20100210816 | NMDAR Biomarkers for Diagnosing and Treating Cerebral Ischemia - Provided are methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression, and (2) ischemic conditions in the central and peripheral nervous systems. Further provides are therapeutic strategies and interventions for the treatment and prevention of stroke, cardiovascular disease, and ischemic lesions in the brain and peripheral nervous system, and pulmonary disorders based on the results of such diagnoses. | 08-19-2010 |
20100210817 | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use - The present invention provides molecular weight markers for accurate determination of the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. | 08-19-2010 |
20100210818 | NUCLEIC ACIDS ENCODING THE HUMAN ALEX1 PROTEIN - The present invention provides a novel protein containing an armadillo repeat, a gene encoding this protein, and production and use thereof. The present inventors identified a gene named ALEX1 encoding a human-derived novel armadillo repeat-containing protein. It was clarified that ALEX1 interacts with several proteins including insulin-degrading enzyme, presenilin-1, and JNK interacting protein 1. This gene shows significantly decreased expression in cancer cells. The protein ALEX1 and the gene encoding this protein are usable as tools in testing for diseases such as cancer and Alzheimer's disease and developing pharmaceutical agents. | 08-19-2010 |
20100240866 | MODIFIED GHERLIN PEPTIDES - The present invention provides a novel peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof. | 09-23-2010 |
20100261875 | Peptides that specifically bind HGF receptor (CMET) and uses thereof - A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed. | 10-14-2010 |
20100261876 | NOVEL METHODS OF SYNTHESIS FOR THERAPEUTIC ANTIVIRAL PEPTIDES - Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides. | 10-14-2010 |
20100273979 | COMPOSITIONS, METHODS AND USES - The present invention relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for the treatment of disease in mammals including humans. | 10-28-2010 |
20100273980 | FUNGAL PEPC INHIBITOR - The present invention relates to an isolated polypeptide having PepC inhibitory activity as well as to a method for producing a heterologous polypeptide of interest in an | 10-28-2010 |
20100273981 | Use of Silintaphin for the Structure-Directed Fabrication of (Nano)Composite Materials in Medicine and (Nano)Technology - The invention concerns the application of silintaphin-1 in the sustainable fabrication of hierarchically ordered silica structures from nano- to macro-scale at environmentally benign conditions and low energy costs (low temperature, low pressure, absence of caustic chemicals). | 10-28-2010 |
20100286365 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME - Peptide-peptidase inhibitor conjugate molecules and methods of manufacture thereof are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders. | 11-11-2010 |
20100286366 | POLYPEPTIDE LIBRARIES WITH A PREDETERMINED SCAFFOLD - Populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLNDSQ or AKYAKEXXXAXX EIXXLPNLTX XQXXAFIXKL XDDPSQSSEL LSEAKKLNDS Q, wherein each X individually corresponds to an amino acid residue which is varied in the population are disclosed. Also populations of polynucleotides, wherein each member encodes a member of a polypeptide population are disclosed. Furthermore, combinations of such polypeptide populations and such polynucleotide populations are disclosed, wherein each member of polypeptide population is physically or spatially associated with the polynucleotide encoding that member via means for genotype-phenotype coupling. Furthermore, methods for selecting a desired polypeptide having an affinity for a predetermined target from a population of polypeptides, isolation of a polynucleotide encoding a desired polypeptide having an affinity for a predetermined target, identifying a desired polypeptide having an affinity for a predetermined target, selecting and identifying a desired polypeptide having affinity for a predetermined target, and production of a desired polypeptide having an affinity for a predetermined target are disclosed. | 11-11-2010 |
20100292434 | IGF-1R BINDING POLYPEPTIDES AND THEIR USE - This invention relates to polypeptides which bind to IGF-1R and to applications of those polypeptides in medicine, veterinary medicine, diagnostics and imaging. | 11-18-2010 |
20100292435 | INSULINOTROPIC PEPTIDE SYNTHESIS USING SOLID AND SOLUTION PHASE COMBINATION TECHNIQUES - The present invention relates to the preparation of insulinotropic peptides that are synthesized using a solid and solution phase (“hybrid”) approach. Generally, the approach includes synthesizing three different peptide intermediate fragments using solid phase chemistry. Solution phase chemistry is then used to couple the second fragment and the first fragment. Alternatively, a different second fragment is coupled to a first fragment in the solid phase. Then, solution phase chemistry is then used to add the third fragment, whereby the third fragment is coupled to the coupled first and second fragments in the solution phase. The present invention is very useful for forming insulinotropic peptides such as GLP-1(7-36) and its natural and non-natural counterparts. | 11-18-2010 |
20100298531 | PMMA BINDING PEPTIDES - Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface. | 11-25-2010 |
20100298532 | PMMA BINDING PEPTIDES - Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface. | 11-25-2010 |
20100298533 | PMMA BINDING PEPTIDES - Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface. | 11-25-2010 |
20100298534 | PMMA BINDING PEPTIDES - Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface. | 11-25-2010 |
20100298535 | PMMA BINDING PEPTIDES - Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface. | 11-25-2010 |
20100305304 | NON-NATURAL PROTEINACEOUS SCAFFOLD MADE OF THREE NON-COVALENTLY ASSOCIATED PEPTIDES - The present invention is related to a non-natural, thermodynamically stable, proteinaceous scaffold consisting of three non-covalently associated peptides, wherein each peptide sequence comprises less than fifty amino acid residues and wherein at least 50% of the said residues are substitutable amino acids into at least ten different amino acid residue types. The present invention is further related to a non-natural, triple-stranded, parallel alpha-helical coiled coil scaffold wherein each of the three constituting peptide sequences comprise between 2 and 7 consecutive heptad repeats, wherein at least 50% of the core residues are isoleucines, wherein all non-core residues are alanines, and wherein the constituting peptide sequences remain associated under physical conditions that are significantly different from physiological conditions. | 12-02-2010 |
20100311945 | HDM2-Inhibitor Complexes and Uses Thereof - The present invention includes crystallized HDM2 peptides as well as descriptions of the X-ray diffraction patterns of the crystals. The diffraction patterns allow the three dimensional structure of HDM2 to be determined at atomic resolution so that ligand binding sites on HDM2 can be identified and the interactions of ligands with HDM2 amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MDM2 and HDM2 oncoproteins. | 12-09-2010 |
20100317826 | NEOPLASM SPECIFIC ANTIBODIES AND USES THEREOF - The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms. | 12-16-2010 |
20100317827 | Method of Purifying a Peptide - The invention relates, interalia, to the field of purification of peptides, notably cyclic or non-cyclic peptides their analogs or derivatives thereof. More particularly, the invention relates to a simplified and optimized purification process of cyclic peptides from a composition comprising the said peptide and at least one related impurity by chromatographic procedures enabling high yields, selectivity and purity of the desired end product. The improved process is particularly useful for the preparation of eptifibatide, exenatide, atosiban, nesiritide and their respective derivatives and analogs. The polypeptides are prepared in high purity of at least about 96%, and preferably at least about 99%. | 12-16-2010 |
20110015368 | CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to an activated peptide derived from the CD4 receptor, which is capable of coupling by covalent bonding to an organic molecule and thus makes it possible to generate multiple potentially antiviral derivatives. The present invention also relates to a conjugated molecule comprising the CD4-receptor-derived peptide and an organic molecule, preferably the GPR1 peptide or a polyanion. Such a conjugated molecule can in particular be used in antiviral treatments, in particular the treatment of AIDS. The invention also relates to the methods for preparing the activated peptide derived from the CD4 receptor and the conjugated molecule. | 01-20-2011 |
20110015369 | Detection Of Truncation Mutations By Mass Spectrometry - This invention relates to the detection and analysis by mass spec of nascent proteins, and in particular truncated proteins, translated within cellular or cell-free translation systems. N-terminal and C-terminal epitopes introduced into these nascent proteins permit rapid and efficient isolation, as well as mass difference. | 01-20-2011 |
20110021746 | UNIVERSAL FIBRONECTIN TYPE III BINDING-DOMAIN LIBRARIES - Fibronectin Type III (FN3) polypeptide libraries are described, along with their use in identifying fibronectin-type binding peptides having hign binding affinities, e.g., greater than 300 nM, for VEGFR2 or Axl proteins. | 01-27-2011 |
20110028687 | FAMILY OF IMMUNOREGULATORS DESIGNATED LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTORS (LIR) - A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies to LIR family members. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function. | 02-03-2011 |
20110046346 | BIOMATERIAL WITH FUNCTIONALISED SURFACES - There is provided a biomaterial having a functionalised surface which comprises bi-functional semi-dendrimers. The biomaterial may be ceramic, metallic and/or polymeric. It will usually be in the form of a solid, but could be a semi-solid or hydrogel. There is also provided a method of making a biomaterial having a functionalised surface which comprises bi-functional semi-dendrimers, said method comprising adsorbing, grafting or synthesising in situ bi-functional semi-dendrimers onto the surface of a biomaterial. There is further provided a biomedical device which is coated with or formed from a biomaterial having a functionalised surface which comprises bi-functional semi-dendrimers. The biomedical device may be a medical implant, for example, such as a stent, artificial hip joint or replacement heart valve. FIG. | 02-24-2011 |
20110054146 | Preparation of Low Molecular Weight Polylysine and Polyornithine in High Yield - The present invention generally relates to the large-scale (e.g., greater than 1 kg scale) preparation of low molecular weight polylysine or polyornithine in high yield by preparing a polylysine or polyornithine having a weight average molecular weight from about 12,500 Daltons to about 22,000 Daltons and hydrolyzing it to produce a polylysine or polyornithine having a weight average molecular weight from about 5,500 Daltons to about 12,000 Daltons. In preferred embodiments, the polymer is a homopolymer of poly-L-lysine. | 03-03-2011 |
20110054147 | MOLECULAR WEIGHT MARKERS FOR MEMBRANE PROTEINS - The present invention provides a novel membrane protein molecular weight marker. | 03-03-2011 |
20110092670 | VARIANTS DERIVED FROM ACTRIIB AND USES THEREFOR - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand. | 04-21-2011 |
20110098442 | PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - Peptides and peptide derivatives of the following general Formula (I): H | 04-28-2011 |
20110098443 | Anti-GLP-1R Antibodies and Their Uses - The present invention relates to antibodies reactive with GLP-1R, and methods of making and using them. | 04-28-2011 |
20110098444 | METHODS OF PREPARATION AND COMPOSITION OF PEPTIDE CONSTRUCTS USEFUL FOR TREATMENT OF RHEUMATOID ARTHRITIS - The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of autoimmune diseases, specifically rheumatoid arthritis (RA) and compositions containing same, methods for producing same and methods for using same; wherein the peptide constructs have the formula P | 04-28-2011 |
20110105721 | PEPTIDES - Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described. | 05-05-2011 |
20110118439 | Three-Dimensional Structure Of The Amyloid Precursor Protein Intracellular Domain (AICD) In Complex With Human FE65-PTB2 - The present invention relates to a three-dimensional structure of the intracellular domain (AICD) of human amyloid precursor protein (APP695) in complex with human Fe65-PTB2 (i.e. a protein-complex comprising the intracellular domain (AICD) of human amyloid precursor protein (APP695) and the human Fe65-PTB2), as well as to methods and uses of said three-dimensional structure for identifying ligands which modify the interaction between the AICD and the Fe65-PTB2. Moreover, the present invention relates to pharmaceutical compositions which contain one or more of such identified ligands for the prevention or treatment of neurodegenerative disorders. | 05-19-2011 |
20110124840 | Synthesis of Homopolymers and Block Copolymers - The present invention relates to the field of polymer chemistry and more particularly to homopolymers and block copolymers and methods of preparing the same. | 05-26-2011 |
20110124841 | Polypeptides Modified by Protein Trans-Splicing Technology - The present invention relates to a method of preparing modified polypeptides, by linking a target polypeptide to a carrier molecule that is designed to bear one or more water-soluble polymer molecules, via protein trans-splicing. The polymer molecules can be attached to the carrier molecule either before or after ligation to the target polypeptide. Novel protein trans-splicing elements (known as “split inteins”) and trans-splicing partners are also provided. | 05-26-2011 |
20110130541 | Inhibitors of Bacterial Tyrosine Kinase and Uses Thereof - A compound comprising a peptide moiety comprising, consisting essentially of, or consisting of, the peptide sequence of a tyrosine cluster YC of the BY-kinase of a Gram positive or Gram negative bacteria, or a fragment or an analogue thereof, and an adenine peptide analogue PNA(A), whereas the peptide moiety and the PNA are linked together. The compound is useful as an inhibitor of bacterial tyrosine kinase. | 06-02-2011 |
20110184146 | ANTIOXIDANT POLYPEPTIDE AND A PROCESS FOR ISOLATION AND PURIFICATION OF THE SAME - A polypeptide is isolated from Turmeric ( | 07-28-2011 |
20110190473 | LEPTIN PEPTIDE ANTAGONISTS - Disclosed herein are peptides comprising a leptin sequence and methods for their use in preventing ObR signaling in a leptin-responsive cell. A leptin peptide of the present invention binds to but does not activate ObR signaling in a leptin-responsive cell, thereby inhibiting the up-regulatory effects of leptin on ObR signaling in the leptin-responsive cell. Administration of the peptide effectively prevents embryo implantation in a mammal to which the peptide has been administered. Also disclosed herein is a method for identifying a peptide antagonist of ObR, wherein the peptide comprises a leptin sequence. | 08-04-2011 |
20110201780 | NOVEL DEATH DOMAIN PROTEINS - In accordance with the present invention, there are provided novel Death Domain (DD), Death Effector Domain (DED) and NB-ARC domain proteins. The invention also provides nucleic acid molecules encoding DD, DED and NB-ARC domain proteins, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention DDs, DEDs or NB-ARC domains. Such DDs, DEDs and NB-ARC domains and/or anti-DD, anti-DED or anti-NB-ARC domain antibodies are useful for discovery of drugs that suppress infection, autoimmunity, inflammation, allergy, allograft rejection, sepsis, and other diseases. | 08-18-2011 |
20110207911 | POLYPEPTIDE DERIVED FROM THE RYANODINE RECEPTOR THAT INHIBITS CALCIUM LEAKAGE - A polypeptide exhibiting the effect of inhibiting Ca | 08-25-2011 |
20110230639 | IMMUNOMODULATORY PEPTIDES - The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention. | 09-22-2011 |
20110230640 | METHODS FOR CHARACTERIZING GLYCOPROTEINS AND GENERATING ANTIBODIES FOR SAME - The invention provides methods for preparing a peptide as an immunogen to generate an antibody specific for the deglycosylated form of a glycopolypeptide by preparing a peptide that includes an N-linked glycosylation site of said glycopolypeptide and identifying a peptide sequence that includes said glycosylated site and preparing said peptide wherein N of said site is converted to D. | 09-22-2011 |
20110275787 | CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY - The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule. | 11-10-2011 |
20110282030 | NATURIURETIC POLYPEPTIDES - This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without lowering blood pressure. Methods and materials for inducing natriuretic activities within a mammal also are provided. | 11-17-2011 |
20110288269 | Design of Spacers To Increase The Expression of Recombinant Fusion Proteins - The present invention relates to fusion proteins. The invention specifically relates to compositions and methods of Tf-based fusion proteins that demonstrate a high-level expression of transferrin (Tf)-based fusion proteins by inserting a helical linker between two protein domains. | 11-24-2011 |
20110294980 | Polymer Conjugate Of Folic Acid Or Folic Acid Derivative - Disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein an amide bond is not used. The compound has chemical stability and adequate drug release rate in the living organism. Specifically disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein a substituent represented by formula (I) is bonded to a carboxy group of a block copolymer which is composed of a polyethylene glycol and a polymer having a carboxy group in a side chain, or a pharmacologically acceptable salt thereof. | 12-01-2011 |
20110313131 | REVERSED PHASE HPLC PURIFICATION OF A GLP-1 ANALOGUE - The invention comprises a process for the purification of a GLP-1 peptide analogue applying reversed phase high performance liquid chromatography (RP-HPLC). | 12-22-2011 |
20110319593 | PROCESS FOR THE PRODUCTION OF BIOLOGICALLY ACTIVE HIV-1 TAT PROTEIN - Tat protein produced in bulk culture is inactive when induced at conventional optical densities but can be obtained in biologically active form when induced during the logarithmic growth phase. | 12-29-2011 |
20120004392 | SELECTIVE GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES - GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions (11, 16, 20, 24) and/or (28) of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position (2) and one or more of positions (3, 5, 7), and (10), and/or a deletion of one or more of amino acids (31) to (33) and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. | 01-05-2012 |
20120004393 | Potent Compstatin Analogs - Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. | 01-05-2012 |
20120004394 | IMMUNOSUPPRESSIVE PEPTIDE - This invention relates to medicine, namely to the family of immunosuppressive peptides (ISP) suppressing a wide range of specific links (components) of human immune system. The desired result of making it possible to extend functionalities is achieved by means of an immunosuppressive peptide, the formula of which has variable positions with two (X) or three (Y) amino-acid substitutions : | 01-05-2012 |
20120016102 | NON-TOXIC BIOFILM INHIBITOR - The present invention relates to a composition, device and method for preventing or inhibiting biofilm formation on biotic or abiotic surfaces. The composition comprises a peptide based on the C-terminal receptor binding domain of | 01-19-2012 |
20120029168 | METHOD FOR AMELIORATING PAIN BY MODIFICATION OF NMDA RECEPTORS THROUGH INHIBITION OF SRC - The present invention provides a method for ameliorating inflammatory and/or neuropathic pain in a subject by modifying the activity of N-methyl-D-aspartate (NMDA) receptors in cells of the subject by inhibition of the interaction of the unique domain of the tyrosine kinase Src enzyme and the NMDA receptor complex. | 02-02-2012 |
20120046443 | Novel biomimetic peptoid polymers - The present invention provides for novel peptoid oligomers that are capable of self-assembling into two-dimensional sheet structures. The peptoid oligomers can have alternately hydrophilic or polar side-chains and hydrophobic or apolar side-chains. The peptoid oligomers, and the two-dimensional sheet structures, can be applied to biological applications where the peptoid plays a role as a biological scaffold or building block. Also, the two-dimensional sheet structures of the present invention can be used as two-dimensional nanostructures in device applications. | 02-23-2012 |
20120059148 | NON-NATURALLY OCCURRING LIPOPROTEIN PARTICLE - Non-naturally occurring lipoprotein particles, process for preparing such particles and uses thereof. | 03-08-2012 |
20120083584 | DENGUE SEROTYPE 1 ATTENUATED STRAIN - The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain. | 04-05-2012 |
20120083585 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 04-05-2012 |
20120083586 | NMDAR BIOMARKERS FOR DIAGNOSING AND TREATING CEREBRAL ISCHEMIA - The present invention relates to methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression, and (2) ischemic conditions in the central and peripheral nervous systems. | 04-05-2012 |
20120088902 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders and disorders and conditions associated with excess fluid and/or salt retention as well as other conditions and disorders are described. The compositions feature polypeptides that activate the guanylate cyclase C (GC-C) receptor. | 04-12-2012 |
20120101255 | PEPTIDE-BASED REGULATION OF GAP JUNCTIONS - The present invention relates to proteins and polypeptides as well as methods of using these proteins and polypeptides to: identify the location of an RXP-binding domain of Cx43CT, modulate a Cx43 gap junction channel, screen for compounds that modulate Cx43CT, and measure Cx43CT-binding affinity of a compound that binds to Cx43CT. | 04-26-2012 |
20120130044 | Stable Analogs of Peptide and Polypeptide Therapeutics - The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof. | 05-24-2012 |
20120130045 | BIOMOLECULE-POLYMER CONJUGATES AND METHODS OF MAKING SAME - Disclosed herein are biomolecule-polymer conjugates of Formula 1, as well as methods of preparing same and kits for preparing same. | 05-24-2012 |
20120149870 | Sequentially arranged streptavidin-binding modules as affinity tags - The present invention relates to sequentially arranged streptavidin-binding binding modules which may in particular be used as affinity tags. The affinity tags comprise at least two individual modules capable of mediating avidic binding to streptavidin. | 06-14-2012 |
20120149871 | Synthetic, Defined Fibronectin Mimetic Peptides And Surfaces Modified With The Same - The present invention discloses compositions for applications that mimic fibronectin coated surfaces. Advantageously, such compositions provide an animal free (xeno-free, and human-component-free), synthetic, chemically defined surface that mimics at least one of the functionalities of fibronectin. | 06-14-2012 |
20120157659 | AFFINITY PEPTIDES AND METHOD FOR PURIFICATION OF RECOMBINANT PROTEINS - This invention describes a process for separating a fusion protein or polypeptide in the form of its precursor from a mixture containing said fusion protein and impurities, which comprises contacting said fusion protein with a resin containing immobilized metal ions, said fusion protein covalently operably linked directly or indirectly to an immobilized metal ion-affinity peptide, binding said fusion protein to said resin, and selectively eluting said fusion protein from said resin. | 06-21-2012 |
20120157660 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. | 06-21-2012 |
20120165505 | Beta Helical Peptide Structures Stable in Aqueous and Non-Aqueous Media - Disclosed are peptide structures that are stable in aqueous and non-aqueous media where a first linear peptide chain comprising alternating D,L- or L,D-amino acids having an N and C termini is joined by at least one turn region to a second linear peptide chain comprising alternating D,L- or L,D-amino acids having an N and C termini. The peptide chains can be joined at the C terminus of one of the linear peptide chains with an N terminus of the other linear peptide chain, a C terminus of one of the linear peptide chains with a C terminus of the other linear peptide chain, or an N terminus of one of the linear peptide chains with an N terminus of the other linear peptide chain. | 06-28-2012 |
20120184710 | BORRELIA ANTIGENS - The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from | 07-19-2012 |
20120184711 | NOVEL POLYPEPTIDE, AN AFFINITY CHROMATOGRAPHY MATERIAL, AND A METHOD FOR SEPARATING AND/OR PURIFYING IMMUNOGLOBULIN - A mutant of the polypeptide Protein A, wherein immunoglobulin binding properties can be altered by changing temperature under the conditions of pH 5-9, below 60° C. The use of the mutant Protein A include the use thereof as a ligand coupled to an affinity chromatography support for the purification of immunoglobulins by affinity chromatography, wherein the immunoglobulins is eluted by changing temperature and thereby the conformation of the mutant Protein A. | 07-19-2012 |
20120190819 | SCAFFOLD POLYPEPTIDES FOR HETEROLOGOUS PEPTIDE DISPLAY - The present invention relates to the use of Stefin A as a scaffold protein for the display of inserted peptides, particularly wherein the Stefin A is a human Stefin A. Several mutations are advantageously made in the wild type stefin A sequence to improve it as a scaffold; preferably the Stefin A comprises a heterologous peptide insertion at the Leu 73 site. Furthermore, preferably the scaffold protein comprises a V48D mutation; preferably the scaffold protein comprises a G4W mutation. Preferably the scaffold comprises Leu73, V48D and G4W mutations. The invention also relates to the scaffold proteins themselves, in particular a stefin A polypeptide having the Leu73, V48D and G4W mutations, such as shown as SEQ ID NO: 1. The invention also relates to a method for identifying binding proteins and to peptide A (RLNKPLPSLPV) and its use in treating yeast infections. | 07-26-2012 |
20120232248 | THERAPEUTIC AGENT FOR PULMONARY SMALL CELL CARCINOMA - The invention aims to clarify further functions of a TCTA protein-derived peptide and provide a novel application of the peptide. The invention provides a therapeutic agent for pulmonary small cell carcinoma or a cell growth inhibitor of pulmonary small cell carcinoma, comprising any peptide described in SEQ ID NOs 1 to 5. | 09-13-2012 |
20120253009 | THROMBOPOIETIC COMPOUNDS - The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal. | 10-04-2012 |
20120283411 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders and disorders and conditions associated with excess fluid and/or salt retention as well as other conditions and disorders are described. The compositions feature polypeptides that activate the guanylate cyclase C (GC-C) receptor. | 11-08-2012 |
20120289679 | NOVEL MITE ALLERGEN - A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided:
| 11-15-2012 |
20120289680 | CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION - The present invention relates to a chromatography ligand, which comprises Domain C from | 11-15-2012 |
20130035469 | Antimicrobial Peptides and Methods of Use - Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, specificity, resistance to degradation desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides result from structure-based rational design relating to antimicrobial peptide V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Some peptides contain one or more (or all) amino acids in the D configuration. Compositions disclosed herein have useful clinical potential as antibiotics including broad spectrum antibiotics. | 02-07-2013 |
20130041132 | CHEMICAL PREPARATION OF UBIQUITIN THIOESTERS AND MODIFICATIONS THEREOF - The present invention discloses latent thioester functionalities attached to the C-terminus of a first polypeptide, or a first fragment thereof having a Cys residue at its N-terminus, and a process using this functionality for the preparation of polypeptide thioesters, in particular of ubiquitin thioesters, this process comprising preparing a polypeptide or a fragment thereof, being attached to a latent thioester functionality, which can then be ligated with a second polypeptide fragment, followed by selective activation of the latent thioester functionality group, to provide the requested polypeptide thioester. There are also provided the polypeptides obtained by this method, specific unnatural amino acids useful to be incorporated within the polypeptide thioesters, and kits for preparing them. | 02-14-2013 |
20130041133 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES - In an embodiment the instant invention discloses a modular composition comprising 1) an oligonucleotide; 2) one or more linkers, which may be the same or different, selected from Table 1, wherein the linkers are attached to the oligonucleotide at any 3′ and/or 5′ end; 3) one or more peptides, which may be the same or different, selected from SEQ ID NOs: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide. | 02-14-2013 |
20130085260 | METHOD FOR THE IDENTIFICATION OF T CELL EPITOPES - A novel method to identify relevant T-cell epitopes recognized by CD8 | 04-04-2013 |
20130096276 | PROTEIN CAPABLE OF BINDING SPECIFICALLY TO IMMUNOGLOBULIN, AND IMMUNOGLOBULIN-BINDING AFFINITY LIGAND - An object of the present invention is to create a novel engineered Protein A ligand having better antibody dissociation properties in the acidic condition compared with known engineered Protein A ligands. The present invention provides a protein having an affinity for an immunoglobulin, including an amino acid sequence obtained by introducing, into an amino acid sequence derived from any of E, D, A, B and C domains of Protein A, at least one amino acid substitution at any one or more of amino acid residues corresponding to positions 31 to 37 of the A, B and C domains (positions 29 to 35 of the E domain, positions 34 to 40 of the D domain), which are conserved in all the domains, the protein having a lower affinity for an Fab region of an immunoglobulin than a protein having the amino acid sequence before introduction of the substitution. | 04-18-2013 |
20130116405 | COMPOSITIONS COMPRISING MODIFIED COLLAGEN AND USES THEREFOR - The invention provides modified collagen and related therapeutic and diagnostic methods. | 05-09-2013 |
20130158233 | METHOD FOR SIMULTANEOUSLY DETECTING AN ANTIGEN OF, AND AN ANTIBODY, AGAINST, AN INFECTIOUS MICROORGANISM - The invention relates to a method for detecting, in vitro, an infection with a microorganism, such as the hepatitis C virus, in a biological sample, by simultaneously detecting an antigen of this microorganism and the antibodies against this same antigen, and also to the reagents and kits implementing this method. | 06-20-2013 |
20130165626 | ANTIFREEZE PROTEIN - An objective of the present invention is to provide an antifreeze protein which is capable of being efficiently produced on an industrial level at low cost and which is safe and has an excellent antifreezing activity for use on a practical level. Also, an objective of the present invention is to provide a polypeptide that corresponds to the active part of the antifreeze protein; a composition, a food, a biological sample protectant and a cosmetic containing the antifreeze protein or the polypeptide; and an antibody that specifically reacts with the antifreeze protein or the polypeptide. The antifreeze protein according to the present invention is characterized in being derived from a plant and having a specific amino acid sequence or being a plant seed protein. | 06-27-2013 |
20130165627 | KISSPEPTIN-54 DETECTION BY TANDEM MASS SPECTROMETRY - Methods are described for measuring the amount of a kisspeptin-54-derived peptides in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying a kisspeptin-54 derived peptides in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques. | 06-27-2013 |
20130165628 | Double Binding Constructs - The disclosure provides methods and materials for improving the pharmacokinetic properties of drugs. For example, a construct is provided having a drug covalently joined to first and second ligands, or a drug covalently joined to a first ligand and a molecular weight increasing moiety. The ligands have affinity for binding partners, and in a physiological fluid, an equilibrium forms between bound and free forms of the construct. The constructs retain most of the drug's activity while simultaneously increasing half life. | 06-27-2013 |
20130172529 | METHOD FOR SYNTHESIZING THYMOSINS - The invention relates to a method for obtaining thymosins and/or the pharmaceutically acceptable salts thereof by means of solid-phase synthesis on polymeric supports, which comprises the steps of linearly synthesizing the thymus-derived peptides in solid phase, incorporating at least one Thr or Ser in the sequence, in pseudoproline dipeptide form, obtaining the thymosins by treating the peptidyl resin with trifluoroacetic acid, and purifying the thymosins by RP-HPLC. The present invention also protects the isolated and/or purified compound obtained by means of said method and also the use thereof in the preparation of a medicinal product. | 07-04-2013 |
20130172530 | Novel JNK Inhibitor Molecules - The present invention relates to novel JNK inhibitor molecules. The present invention furthermore relates to methods for raising antibodies against such JNK inhibitor molecules as well as to the respective antibodies and cells producing said antibodies. | 07-04-2013 |
20130184434 | Peptide Toxin Formulation - Procedures are described which use solvents to increase the topical insecticidal activity of toxic insect peptides. These procedures comprise drying the peptides, if needed, followed by the addition of either: 1) a polar organic solvent, with or without water, to a dried peptide, or 2) the addition of polar aprotic solvent or other adjuvant to the dried peptide, followed by the addition of either: 1) a polar organic solvent, with or without water, (where a polar aprotic solvent is added first) or 2) a polar aprotic solvent or other adjuvant to the peptide polar organic solvent (where the polar organic solvent is added first), to the peptide formulation. | 07-18-2013 |
20130197191 | Binding Proteins That Bind to Human FGFR1c, Human Beta-Klotho and Both Human FGFR1c and Human Beta-Klotho - Binding proteins that specifically bind to β-Klotho or portions thereof, FGFR1c or portions thereof, or both FGFR1c and β-Klotho, and optionally other proteins as well are provided. Coding sequences, methods of treatment and pharmaceutical compositions are also provided. | 08-01-2013 |
20130217857 | ERBB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF - Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 08-22-2013 |
20130231458 | POLYPEPTIDE FOR PREVENTING AND TREATING CELL HYPERPLASIA - A polypeptide for preventing and treating cell hyperplasia is applied to preventing potential objects from cell hyperplasia and treating objects having cell hyperplasia. The polypeptide comprises an amino acid sequence listed as SEQ ID NO: 1. The amino acid sequence can effectively inhibit growth of lung cancers. The polypeptide would not cause significant evil reactions or obvious side effects even though it is applied at a high dose (50 mg/Kg) and a high frequency (5 times per week). | 09-05-2013 |
20130245224 | AFFINITY CHROMATOGRAPHY MATRIX - The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the adsorbed immunoglobulin containing proteins; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins. The method improves upon previous separation methods in that each of the ligands comprises one or more of a protein A domain (E, D, A, B, C), or protein Z, or a functional variant thereof, with at least one of the monomers having a substitution of the C-terminal most proline residue after the third alpha-helix. | 09-19-2013 |
20130253169 | PEPTIDE CAPABLE FOR BINDING TO GOLD - The present invention provides a novel peptide capable for binding to gold. The peptide consists of an amino acid sequence represented by SQMMGHMGHGNMNHMNHGGKFDFHH. | 09-26-2013 |
20130267679 | PEPTIDE CAPABLE FOR BINDING TO CARBON - Provided is a novel peptide capable for binding to carbon. The peptide consists of an amino acid sequence represented by SQMMGHMGHGNMNHMNHGGKFDFHH. | 10-10-2013 |
20130267680 | TOTAL CHEMICAL SYNTHESIS OF UBIQUITIN, UBIQUITIN MUTANTS AND DERIVATIVES THEREOF - The present invention relates to the field of total chemical synthesis of ubiquitin and related peptides. More in particular, a method is provided of solid phase synthesis of ubiquitin, ubiquitin mutants and derivatives thereof. It was the object of the present invention to provide an approach for the total chemical synthesis of ubuiqitin, which allows for the chemical synthesis of virtually any Ub mutant and giving high overall efficiency and purity. The present inventors have surprisingly found that this object can be realized with a method relying on incorporation of special amino acid building blocks. This approach was found to allow for exceptionally high yields of up to 14% and to provide an synthetic entry into virtually any ubiquitin derivative. | 10-10-2013 |
20130274437 | STABILIZED AMYLOID-BETA OLIGOMERS AND USES THEREOF - The present invention pertains to stabilized Aβ oligomer compositions. Methods for generating stabilized Aβ oligomer compounds are also provided herein. Additionally, screening assays employing the Aβ oligomer compounds and methods for generating therapeutics with the Aβ oligomers are also provided. In a particular embodiment, the Aβ oligomer described herein is comprised of Aβ42 peptide. | 10-17-2013 |
20130274438 | Analogs of ShK Toxin and Their Uses in Selective Inhibition of Kv1.3 Potassium Channels - Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore and such fluorophore-tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells. | 10-17-2013 |
20130281659 | WELL-DEFINED OLIGOMERS OF UBIQUITIN AND UBIQUITIN-LIKE POLYPEPTIDES, AND METHODS FOR PREPARING SAME - The present technology relates to well-defined oligomers comprising two or more monomers wherein each monomer is independently selected from a ubiquitin polypeptide or a ubiquitin-like polypeptide, and the monomers are covalently linked to each other via a thioether group or groups. Further provided are monomer building blocks and methods of making the monomers and oligomers. | 10-24-2013 |
20130296531 | BLOCK COPOLYMERS FOR STABLE MICELLES - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications. | 11-07-2013 |
20130338339 | AFFINITY CHROMATOGRAPHY MATRIX - The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins. The method improves upon previous separation methods in that each of the ligands comprises one or more of a protein A domain (E, D, A, B, C), or protein Z, or a functional variant thereof, with at least one of the monomers having a substitution of the Asparagine or Histidine at the position corresponding to H18 of B domain of Protein A or Protein Z, and wherein the ligand provides an increase in elution pH compared to non-substituted ligand. | 12-19-2013 |
20130345392 | EDN3-LIKE PEPTIDES AND USES THEREOF - This application discloses novel EDN3-like polypeptides. One such short polypeptide is EDN3 97-140, which is a 44 amino acid peptide that stimulates GLP-1 secretion in enteric cells and inhibits gluconeogenesis in hepatic cells. EDN3 97-140, as well as other EDN3-like polypeptides provided herein may be used in the study and treatment of a number of indications, including the treatment of metabolic disorders such as obesity and diabetes. | 12-26-2013 |
20130345393 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD - The purpose of the present invention is to provide a cross-linked peptide containing a novel non-peptide cross-linked structure, and a method for synthesizing the same. A cross-linked peptide having a novel non-peptide cross-linked structure, a useful intermediate for synthesizing the cross-linked peptide, and a method for synthesizing the novel cross-linked peptide and the intermediate are provided. The cross-linked peptide is characterized by having an —NR— bond in the cross-linked structure. By using the method for synthesizing the cross-linked peptide, a cross-link can be freely designed and an change can be freely made to a cross-link. | 12-26-2013 |
20140005356 | Method for in vivo residue-specific DOPA incorporation into mussel adhesive proteins | 01-02-2014 |
20140005357 | SUPPORT FOR AFFINITY CHROMATOGRAPHY AND METHOD FOR ISOLATING IMMUNOGLOBULIN | 01-02-2014 |
20140005358 | NATRIURETIC POLYPEPTIDES | 01-02-2014 |
20140011978 | EXTRACELLULAR MATRIX HEPARIN-BINDING DOMAINS - Heparin binding peptides derived from a Tenascin (TNC) III1-5 domain or a fibrinogen β15-66 domain have been found that bind certain cytokines with high affinity. Materials and methods for making compositions and devices using these peptides are disclosed. | 01-09-2014 |
20140018519 | Stabilized Fibronectin Domain Compositions, Methods and Uses - A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices. | 01-16-2014 |
20140031520 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES - Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA. | 01-30-2014 |
20140031521 | PLANT MYB TRANSCRIPTION FACTOR HOMOLOGS - This invention relates to an isolated nucleic acid fragment encoding a Myb-related transcription factor. The invention also relates to the construction of a chimeric gene encoding all or a portion of the Myb-related transcription factor, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the Myb-related transcription factor in a transformed host cell. | 01-30-2014 |
20140031522 | NOVEL ALKALI-RESISTANT VARIANTS OF PROTEIN A AND THEIR USE IN AFFINITY CHROMATOGRAPHY - The present invention relates to immunoglobulin (Ig)-binding proteins with alkali-resistance properties. In one embodiment, the present invention provides for a variant of an Ig-binding protein, the variant comprising the Ig-binding protein having at least one asparagine residue substituted with a histidine, a serine, an aspartic acid or a threonine residue. The at least one substitution may confer to the variant Ig-binding protein an increased stability in alkaline solutions when compared to the wild-type Ig-binding. The present invention relates also to matrices for affinity separation of immunoglobulins comprising the Ig-binding proteins of the present invention, and to methods of using the Ig-binding proteins of the present invention to separate immunoglobulins from mixture compositions. | 01-30-2014 |
20140100356 | NOVEL IMMUNOGLOBULIN-BINDING POLYPEPTIDE - An object of the present invention is to provide novel polypeptides that are capable of binding to an immunoglobulin and have high stability against alkali. The present invention relates to proteins having the amino acid sequence of SEQ ID No:1 or 2. | 04-10-2014 |
20140107315 | PROTEIN FOR AFFINITY-SEPARATION MATRIX - An object of the present invention is to provide a technique to create novel engineered protein ligands that, when immobilized through a lysine residue (its side chain ε-amino group) which allows for efficient immobilization to a carrier, show the optimum binding capacity and binding efficiency to a target molecule. The present invention provides an engineered protein having a sequence obtained by replacing all the lysine residues in Protein A, which is the most typical protein ligand, with other amino acids, and adding lysine at a terminal; and an affinity separation matrix in which such an engineered protein is immobilized on a water-insoluble carrier by reductive amination or the like. This affinity separation matrix is characterized by its high binding capacity to a target molecule even when the immobilized amount of the ligand is small. | 04-17-2014 |
20140114051 | BLOCK COPOLYMERS FOR STABLE MICELLES - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications. | 04-24-2014 |
20140121355 | Drug Screening Target For Alzheimer's Disease and Method of Screening Potential Drugs - Drug screening targets and method of screening for potential drugs for treatment or amelioration of Alzheimer's Disease are provided. | 05-01-2014 |
20140128569 | METHOD FOR ACQUIRING A HEAT-STABLE ANTIBODY-DISPLAYED PHAGE - Using a biopanning method, a heat-stable antibody-displayed phage is acquired. More particularly, first, an antibody-displayed phage library aqueous solution containing plural types of antibody-displayed phages is supplied to a support comprising a polypeptide on the surface thereof, so as to bind the plural types of the antibody-displayed phages to the polypeptide specifically. Next, the support is heated to the temperature of not less than 37 degrees Celsius and not more than 70 degrees Celsius, so as to release a portion of the antibody-displayed phages from the support and so as to leave the other antibody-displayed phages on the support selectively. Finally, the other antibody-displayed phages which has been left on the support selectively in the previous step is collected to obtain the heat-stable antibody-displayed phage. | 05-08-2014 |
20140135474 | UNIVERSAL FIBRONECTIN TYPE III BINDING-DOMAIN LIBRARIES - Fibronectin Type III (FN3) polypeptide libraries are described, along with their use in identifying fibronectin-type binding peptides having high binding affinities, e.g., greater than 300 nM, for VEGFR2 or Axl proteins. | 05-15-2014 |
20140135475 | ANTIBODIES FOR BINDING TO NON-FUNCTIONAL P2X7 RECEPTORS IN TRIMERIC FORM - The invention relates to a novel epitope on P2X7 receptors, to antibodies for binding to the epitope and to peptides for generating the antibodies. | 05-15-2014 |
20140135476 | CHROMATOGRAPHY LIGAND COMPRISING DOMAIN C FROM STAPHYLOCOCCUS AUREUS PROTEIN A FOR ANTIBODY ISOLATION - The present invention relates to a chromatography ligand, which comprises Domain C from | 05-15-2014 |
20140163201 | MULTISPECIFIC PEPTIDES - The invention relates to a method for providing a multispecific peptide ligand comprising a polypeptide covalently linked to a molecular scaffold at three or more amino acid residues and capable of binding to two or more separate targets, comprising the steps of: (a) providing a first repertoire of polypeptides, each polypeptide comprising two or more reactive groups capable of covalent linkage to a molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; (b) providing a second repertoire of polypeptides as described in (a); (c) joining at least one loop of one or more members of the first repertoire to at least one loop of one or more members of the second repertoire to form at least one polypeptide comprising two loops, and (d) conjugating the composite polypeptide(s) to a molecular scaffold at at least three amino acid positions. | 06-12-2014 |
20140179898 | MUTATED PROTEIN OF PROTEIN A HAVING REDUCED AFFINITY IN ACIDIC REGION AND ANTIBODY-CAPTURING AGENT - A modified protein of an extracellular domain of protein A, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein A, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein A bound with the Fc region of immunoglobulin G, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the Fc region and have a 20% or more ratio of exposed surface area, by histidine residues. Preferably, the modified protein is obtained by the substitution of amino acid residues at sites identified from the analysis of sequences selected from a library constituted by the protein group, by histidine residues. These substitutions may be combined. | 06-26-2014 |
20140179899 | DOUBLE-ACYLATED GLP-1 DERIVATIVES - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1(7-37), and a maximum of ten amino acid modifications as compared to GLP-1(7-37), wherein the first K residue is designated K | 06-26-2014 |
20140187743 | SURFACE-ACTIVE COLLAGEN MEMBRANE BY PEPTIDE - The present invention relates to a membrane having bound thereto an antibacterial peptide that binds to collagen, and more particularly to a collagen membrane comprising a fusion peptide of a collagen-binding peptide and an antibacterial peptide, fixed to the collagen surface. | 07-03-2014 |
20140187744 | Bilirubin Excretion Enhancer - The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an active ingredient, a serum albumin domain II-like protein comprising a serum albumin subdomain IIA. In one embodiment, the serum albumin subdomain IIA has an amino acid sequence of SEQ ID NO: 1. In one embodiment, the serum albumin domain II-like protein is a serum albumin domain II. In one embodiment, the serum albumin domain II comprises the amino add sequence of SEQ ID NO: 4. | 07-03-2014 |
20140194593 | COPOLYMER 1 RELATED POLYPEPTIDES FOR USE AS MOLECULAR WEIGHT MARKERS AND FOR THERAPEUTIC USE - The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases. In addition, the subject invention provides pharmaceutical compositions for the treatment of immune diseases comprising a polypeptide having an identified molecular weight and an amino acid composition corresponding to glatiramer acetate or a terpolymer. | 07-10-2014 |
20140206837 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES - Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA. | 07-24-2014 |
20140213759 | Process For Extraction Of Peptides And Its Application In Liquid Phase Peptide Synthesis - A process for extraction of a peptide from a reaction mixture resulting from a peptide coupling reaction, the reaction mixture containing the peptide and a polar aprotic solvent selected from the group consisting of N,N-dimethylformamide, N,N-dimethylacetamide and N-methyl-2-pyrrolidone, whereby the process includes a step a) and a step b): step a) including the addition of a component a1) and a component a2), whereby component a1) is 2-methyltetrahydrofuran and component a2) is water, to the reaction mixture, so that a biphasic system with an organic layer and an aqueous layer is obtained; step b) including the subsequent separation of the organic layer containing the peptide from the aqueous layer. In an embodiment, a combination of 2-methyltetrahydrofuran and an organic solvent 1 selected from the group consisting of n-heptane, toluene, ethylacetate, isopropylacetate, acetonitrile and tetrahydrofuran is used for the process for extraction. The extraction step is preferably used in a process for preparation of a peptide in liquid phase. | 07-31-2014 |
20140221607 | MONOCLONAL ANTIBODY AND ANTIGENS FOR DIAGNOSING AND TREATING LUNG DISEASE AND INJURY - The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression. | 08-07-2014 |
20140221608 | ACID-CLEAVABLE LINKERS EXHIBITING ALTERED RATES OF ACID HYDROLYSIS - An acid-cleavable peptide linker comprising aspartic acid and proline residues is disclosed. The acid-cleavable peptide linker provides an altered sensitivity to acid-hydrolytic release of peptides of interest from fusion peptides of the formula PEP1-L-PEP2. The inventive linker, L, is described in various embodiments, each of which provides substantially more rapid acid-release of peptides of interest than does a single aspartic acid-proline pair. In an additional aspect, a method of increasing the stability of an acid cleavable linkage to acid hydrolysis is also provided. | 08-07-2014 |
20140256912 | Stabilized Variant MAML Peptides and Uses Thereof - Internally cross-linked peptides derived from human MAML and derivatives thereof which exhibit affinity for the ICN1-CSL complex are described and characterized. The peptides can interfere with NOTCH signaling and are thus useful for treating various disorders, including certain cancers. | 09-11-2014 |
20140275477 | Modification and Compositions of Human Secretoglobin Proteins - Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein. | 09-18-2014 |
20140275478 | Vaccines against Chlamydia sp. - The present invention describes an efficient vaccine against a | 09-18-2014 |
20140296479 | D-APTIDE AND RETRO-INVERSO APTIDE WITH MAINTAINED TARGET AFFINITY AND IMPROVED STABILITY - The present invention is characterized by a D-Aptamer-Like Peptide (D-Aptide) or retro-inverso Aptide which specifically binds to a target comprising: (a) a structure stabilizing region comprising parallel, antiparallel or parallel and antiparallel D-amino acid strands with interstrand noncovalent bonds; and (b) a target binding region I and a target binding region II comprising randomly selected n and m D-amino acids, respectively, and coupled to both ends of the structure stabilizing region. The D-Aptide or retro-inverso Aptide has the sequence of the same or opposite direction to L-Aptide, wherein the stability to proteases is improved while maintaining the affinity to a target compared with L-Aptide. The D-Aptide of the present invention has substantially the same target affinity and a remarkably improved stability compared with L-Aptide which is different from a general technical knowledge. | 10-02-2014 |
20140296480 | PEPTIDE SECRETED BY LACTOBACILLUS PLANTARUM WITH IMMUNOMODULATING FUNCTION - Among the fewer than 10 proteins primarily secreted by the species | 10-02-2014 |
20140309400 | Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Dry Eye Syndrome - The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of dry eye syndrome. | 10-16-2014 |
20140316105 | METHOD FOR MODIFICATION OF ORGANIC MOLECULES - The present invention is directed to a method of alkylating a thiol group (R—S—H) or seleno group (R—Se—H) in a target molecule wherein the method comprises: reacting a target molecule comprising at least one thiol group with a compound of formula (I) or (II): wherein R is an acetyl group or any other acyl group or is a group comprising any one of: or wherein R in formula (II) can also be an alkyl group; and wherein R′ is selected from a group consisting of a hydrogen, a methyl group and an ethyl group. | 10-23-2014 |
20140316106 | INTEGRIN-BLOCKING POLYPEPTIDES AND USES THEREOF - A series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity is provided. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis. Specifically, said series of integrin blockers include polypeptide I, polypeptide II and polypeptide III (see SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3) that can be adopted in treatment of solid tumors and rheumatoid arthritis. This invention also relates to application of these three integrin-blocking polypeptides in preparation of anti-tumor drugs, wherein the tumors that can be treated include those primary or secondary cancers originated from head and neck region or other organs such as brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gallbladder, colon, rectum, ovary, cervix, uterus, prostate, bladder and testicle, as well as melanoma and sarcomas. | 10-23-2014 |
20140336357 | MICROBIAL NANOWIRES - The application describes electrically conductive nanowires, as well as genetically and/or chemically modified nanowires with modified conductive, adhesive and/or coupling properties. | 11-13-2014 |
20140343248 | METHOD FOR ENHANCING IMMUNE RESPONSE WITH PEPTIDE - An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid β peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid β peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine. | 11-20-2014 |
20140357840 | METHOD FOR OBTAINING A DIALYZABLE LEUKOCYTE EXTRACT - The present invention relates to a method for producing a transfer factor. The method comprises the following steps: freezing and thawing of peripheral-blood leukocytes, dialysis, tangential ultrafiltration, identification and quantification using high-resolution, molecular-exclusion liquid chromatography, and in vitro biological validation. The resulting product is suitable for medical use. | 12-04-2014 |
20140378653 | Factor XII Inhibitors for the Treatment of Neurological Inflammatory Disorders - This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided. | 12-25-2014 |
20150018518 | GHRELIN ANALOGUES - The present invention relates, inter alia, to ghrelin analogues and their medical use, for example in the treatment of cachexia, chronic obstructive pulmonary disease, gastrointestinal disorders (e.g., gastroparesis and/or inflammatory disorders such as colitis, gut barrier dysfunction, and ischemia reperfusion injury), loss of body weight, and decreased appetite. | 01-15-2015 |
20150031851 | HMGN2 PEPTIDES AND RELATED MOLECULES THAT SELECTIVELY HOME TO TUMOR BLOOD VESSELS AND TUMOR CELLS - The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided. | 01-29-2015 |
20150031852 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE - Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) at least one cargo moiety. | 01-29-2015 |
20150038674 | USE OF GLP-2 ANALOGUES IN PULMONARY DISEASES FOR THERAPEUTIC PURPOSE - The present invention relates to the use of GLP-2 analogue in an efficient amount for the production of a drug specific to treat a pulmonary disease which IS caused by oxidative stress, inflammation and/or apoptosis in an organism. | 02-05-2015 |
20150038675 | PEPTIDE HAVING AFFINITY FOR SILICON NITRIDE (SI3N4), AND USE THEREOF - The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride. The invention involves a peptide having an affinity for silicon nitride, the peptide comprising (1-1) a peptide having the amino acid sequence of one of SEQ ID NOS: 1, 2 and 23 to 27, (1-2) a peptide that has an affinity for silicon nitride and comprises an amino acid sequence obtained by deleting, adding, and/or substituting one or more amino acids in one of the amino acid sequences indicated in (1-1), or a fragment of one of the peptides. | 02-05-2015 |
20150045535 | Bacillus Licheniformis Chromosome - The present invention relates to an isolated polynucleotide of the complete chromosome of | 02-12-2015 |
20150045536 | UNIVERSAL CARRIER FOR TARGETING MOLECULES TO GB3 RECEPTOR EXPRESSING CELLS - The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein:
| 02-12-2015 |
20150133632 | CONFORMATIONALLY DYNAMIC PEPTIDES - Disclosed are novel peptides that are useful, for example, for detecting target proteins having a β-sheet secondary structure which may be associated with a disease, and for diagnosing and treating such a disease. Related methods and kits also are disclosed. | 05-14-2015 |
20150141616 | Disulfide Stabilized Foldon Polypeptides - Intermolecular disulfide stabilized foldon polypeptides are provided. | 05-21-2015 |
20150299284 | NATRIURETIC POLYPEPTIDES - This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided. | 10-22-2015 |
20150307581 | COMPOSITIONS AND METHODS FOR TREATING ANTIPHOSPHOLIPID SYNDROME - The invention features compositions and methods of using a dimeric inhibitor, e.g., A1-A1, to selectively target β2GPI in β2GPI/antibody complexes. The compositions can be administered to subjects (e.g., a mammal, such as a human) having or likely to develop APS, or one or more symptoms of APS, in order to treat or inhibit the disease or treat or reduce its symptoms. The inhibitors of the invention include two ligand-binding A1 modules, e.g., from ApoER2, connected by a flexible linker. | 10-29-2015 |
20150322127 | NATRIURETIC POLYPEPTIDES WITH UNIQUE PHARMACOLOGIC PROFILES - This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without inducing excessive hypotension. This document also provides methods and materials for inducing natriuretic activities within a mammal. | 11-12-2015 |
20150330991 | METHOD FOR IMPROVING TARGET AFFINITY OF PEPTIDE - The present invention relates to a method for improving the target affinity of a peptide binding to a protein target. The present invention provides a very effective and simple method capable of improving the target affinity of a known peptide in an innovative manner. According to the present invention, the target affinity of the known peptide may be increased, for example, by 1,000 times. The KPI-bipodal peptide binder technique according to the present invention can significantly improve the applicability of the known peptide. | 11-19-2015 |
20150353608 | ANTIBODY-BINDING PEPTIDE - The invention relates to polypeptides consisting of amino acid sequences represented by the following formulas 1 to 4, which have binding activity to an Fc region of immunoglobulin G and can be favorably used in detecting, purifying, immobilizing or removing an antibody, immunoglobulin G or a protein containing an Fc region of immunoglobulin G, | 12-10-2015 |
20150361149 | METHOD FOR DEVELOPMENT OF A PEPTIDE BUILDING BLOCK USEFUL FOR DE NOVO PROTEIN DESIGN - The present invention relates to a top-down symmetric deconstruction approach which provides a novel alternative means to successfully identify a useful polypeptide “building block” for subsequent “bottom-up” de novo design of target protein architecture. The present invention also pertains to a novel peptides isolated by top-down symmetric deconstruction which may be useful for design or directed evolution of novel proteins with novel functionalities. | 12-17-2015 |
20160002286 | CHEMICAL PREPARATION OF UBIQUITIN THIOESTERS AND MODIFICATIONS THEREOF - The present invention discloses latent thioester functionalities attached to the C-terminus of a first polypeptide, or a first fragment thereof having a Cys residue at its N-terminus, and a process using this functionality for the preparation of polypeptide thioesters, in particular of ubiquitin thioesters, this process comprising preparing a polypeptide or a fragment thereof, being attached to a latent thioester functionality, which can then be ligated with a second polypeptide fragment, followed by selective activation of the latent thioester functionality group, to provide the requested polypeptide thioester. There are also provided the polypeptides obtained by this method, specific unnatural amino acids useful to be incorporated within the polypeptide thioesters, and kits for preparing them. | 01-07-2016 |
20160045627 | SHK-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURING AND USING THE SAME - Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO:1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed. | 02-18-2016 |
20160090401 | SELF-ASSEMBLING PEPTIDE CAGES FROM COILED-COIL PEPTIDE MODULES - This invention relates to protein structures, to methods of producing those protein structures, and to peptides used in the formation of the protein structures. | 03-31-2016 |
20160096873 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins. The invention additionally provides methods of identifying and making such improved polypeptides. | 04-07-2016 |
20160101151 | COMPOUNDS AND METHODS OF MODULATING ANGIOGENESIS - A pharmaceutical composition includes a synthetic peptide consisting of about 10 to about 50 amino acids and having an amino acid sequence substantially homologous to consecutive amino acids of a portion of the cytoplasmic domain of at least one of α | 04-14-2016 |
20160152668 | Mutated Immunoglobulin-Binding Protein | 06-02-2016 |
20160159855 | MUTATED IMMUNOGLOBULIN-BINDING POLYPEPTIDES - A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of | 06-09-2016 |
20160159870 | Compositions and Methods of Use for Recombinant Human Secretoglobins - Methods of synthetically producing, formulating and using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 as therapeutic agents to affect long term patient outcomes, such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention, including hospitalization are provided. Methods of producing recombinant human secretoglobins, analytical methods, pharmaceutical compositions, and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided. | 06-09-2016 |
20160166717 | RADIOLABELLING METHOD | 06-16-2016 |
20160168209 | PROTEIN LIGAND FOR AFFINITY ISOLATION MATRIX | 06-16-2016 |
20160175226 | STABILIZED CALCIUM PHOSPHATE COMPLEXES | 06-23-2016 |
20160176918 | COUPLING METHOD FOR PEPTIDE SYNTHESIS AT ELEVATED TEMPERATURES | 06-23-2016 |